We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-12.3%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$784M
AUM Growth
-$237M
Cap. Flow
-$75.7M
Cap. Flow %
-9.66%
Top 10 Hldgs %
46.1%
Holding
163
New
33
Increased
30
Reduced
43
Closed
36

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$37.3M
2
INCY icon
Incyte
INCY
+$11.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.68M
4
SHPG
Shire pic
SHPG
+$8.32M
5
BIIB icon
Biogen
BIIB
+$8.01M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.8M
2
GILD icon
Gilead Sciences
GILD
+$22.2M
3
PFE icon
Pfizer
PFE
+$10.1M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$9.03M
5
VRNT
Verint Systems
VRNT
+$8.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.74%
2 Industrials 4.06%
3 Utilities 2.54%
4 Technology 1.27%
5 Consumer Discretionary 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
51
Alnylam Pharmaceuticals
ALNY
$27.5B
$3.21M 0.41%
40,000
+3,000
+8% +$333K
FWP
52
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$3.18M 0.41%
19,286
-2,143
-10% -$450K
KITE
53
DELISTED
Kite Pharma, Inc.
KITE
$3.17M 0.4%
56,970
– –
TVRD
54
Tvardi Therapeutics
TVRD
$19.7M
$3.14M 0.4%
6,106
+4,809
+371% +$3.22M
ARWR icon
55
Arrowhead Research
ARWR
$11.9B
$3.11M 0.4%
540,000
+65,000
+14% +$409K
ABUS icon
56
Arbutus Biopharma
ABUS
$857M
$3.08M 0.39%
505,000
+250,000
+98% +$2.22M
INSM icon
57
Insmed
INSM
$21.4B
$3.06M 0.39%
165,000
-50,000
-23% -$1.25M
CYNA
58
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$3.06M 0.39%
188,930
-127,518
-40% -$2.07M
TVTX icon
59
Travere Therapeutics
TVTX
$5.2B
$3.04M 0.39%
+150,000
New +$4.44M
TXMD icon
60
TherapeuticsMD
TXMD
$23.5M
$3M 0.38%
10,250
+2,000
+24% +$711K
TJX icon
61
TJX Companies
TJX
$174B
$2.96M 0.38%
+82,992
New +$2.91M
RARE icon
62
Ultragenyx Pharmaceutical
RARE
$2.45B
$2.96M 0.38%
30,700
-17,000
-36% -$1.95M
ONCE
63
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$2.92M 0.37%
+70,000
New +$3.65M
ICPT
64
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.9M 0.37%
17,500
– –
BHC icon
65
Bausch Health
BHC
$2.58B
$2.81M 0.36%
15,750
-30,000
-66% -$7M
EXEL icon
66
Exelixis
EXEL
$13.3B
$2.81M 0.36%
500,000
+100,000
+25% +$544K
FOMX
67
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.79M 0.36%
380,000
– –
RCKT icon
68
Rocket Pharmaceuticals
RCKT
$340M
$2.77M 0.35%
73,750
-21,250
-22% -$976K
MRTX
69
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.75M 0.35%
80,000
-15,000
-16% -$453K
IONS icon
70
Ionis Pharmaceuticals
IONS
$8.6B
$2.75M 0.35%
68,000
+20,000
+42% +$1.04M
PTN
71
Palatin Technologies
PTN
$13.7M
$2.72M 0.35%
2,687
+655
+32% +$752K
FPRX
72
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.69M 0.34%
175,000
+50,000
+40% +$1.07M
ALPN
73
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.62M 0.33%
50,430
-13,320
-21% -$875K
ATXS
74
DELISTED
Astria Therapeutics
ATXS
$2.6M 0.33%
5,458
-1,976
-27% -$1.41M
GNCA
75
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.58M 0.33%
47,150
+9,375
+25% +$930K
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sphera Funds Management held 163 positions worth $784M, down 23% from $1.02B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management withdrew a net $75.7M in Q3 2015, closing 36 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $22.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 51% a quarter earlier, followed by Industrials and Utilities.

Against the trend, Sphera Funds Management opened a new position in Incyte worth $11M.

  • Sphera Funds Management's largest Q3 2015 buy was Incyte: 100,000 shares worth $11M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q3 2015, an estimated $37.3M increase.
  • Sphera Funds Management's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $22.2M.
  • Sphera Funds Management fully exited Merck in Q3 2015, selling an estimated $22.8M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $784M portfolio in Q3 2015.
  • Sphera Funds Management opened 33 new positions and closed 36 in Q3 2015.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $784M.

Based on Sphera Funds Management's 13F filing for Q3 2015, filed 16 Nov 2015.